Abstract
Background: A majority of oncological patients apply add-on white-berry European mistletoe (Viscum album L., VA) extracts to reduce disease- and treatment-related symptoms and to improve health-related quality of life (HRQL). VA extracts exert various antitumor, pro-apoptotic, anti-proliferative, and immunomodulatory effects. Two current meta-analyses attribute life-prolonging and HRQL-improving properties to additive VA therapy. The aim of the present update was to review the current knowledge on VA extracts in clinical oncology. Hereby, we concentrated on studies with the highest clinical relevance in the field of lung, gastric, colorectal and pancreatic, gynaecological, as well as breast cancer applying the anthroposophical mistletoe preparations. Summary: The present update provides a brief overview regarding the use of VA preparations in clinical oncology reviewing current guidelines, systematic reviews, randomized controlled and real-world data studies. We have searched the pubmed.gov database of the National Library of Medicine with the search terms “mistletoe” and “cancer.” We found good evidence of add-on VA therapy to improve the HRQL of patients with breast cancer (American Society of Clinical Oncology – endorsed Society for Integrative Oncology guideline) and of HRQL-improving and survival-prolonging properties of VA therapy in pancreatic cancer. In the field of gastrointestinal, gynaecological, and lung cancer, new or updating integrative and/or oncological guidelines should consider clear recommendations on integrative therapies including VA therapy. Nevertheless, further clinical and real-world data trials need to be performed in this field. Key Messages: Evidence for add-on VA treatment for the improved management of cancer and cancer-related side effects is accumulating. Patients with breast cancer: good evidence for add-on VA therapy to improve the HRQL of oncological patients. Patients with pancreatic cancer: good evidence for add-on VA to improve HRQL and prolong survival. Patients with gastrointestinal, gynaecological, and lung cancer: update of guidelines is recommended with regards to integrative oncological therapies including add-on VA.
Journal Section:
Review Article / Übersichtsarbeit
References
1.
Rostock
M
. Misteltherapie: Ihr aktueller Stellenwert bei der Behandlung von Tumorerkrankungen
. In: Rietbrock
N
, editor. Phytopharmaka IV
. Heidelberg
: Steinkopff Verlag
; 2000
. p. 167
–80
.2.
Horneber
MA
, Bueschel
G
, Huber
R
, Linde
K
, Rostock
M
. Mistletoe therapy in oncology (review)
. Cochrane Collaboration
. 2008
:1
–69
.3.
Münstedt
K
, Entezami
A
, Kullmer
U
. Onkologische Misteltherapie: zur Anwendung und Bewertung der Wirksamkeit durch Ärzte
. Deutsche Medizinische Wochenschrift
. 2000
;125
(41
):1222
–6
.4.
Weis
J
, Bartsch
HH
, Hennies
F
, Rietschel
M
, Heim
M
, Adam
G
, et al. Complementary medicine in cancer patients: demand, patients’ attitudes and psychological beliefs
. Onkologie
. 1998
;21
(2
):144
–9
.5.
Templeton
AJ
, Thurlimann
B
, Baumann
M
, Mark
M
, Stoll
S
, Schwizer
M
, et al. Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors
. BMC Cancer
. 2013
;13
:153
.6.
Thronicke
A
, Oei
SL
, Merkle
A
, Herbstreit
C
, Lemmens
HP
, Grah
C
, et al. Integrative cancer care in a certified cancer centre of a German anthroposophic hospital
. Complement Ther Med
. 2018
;40
:151
–7
.7.
Drozdoff
L
, Klein
E
, Kiechle
M
, Paepke
D
. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy
. BMC Complement Altern Med
. 2018
;18
(1
):259
.8.
Micke
O
, Büntzel
J
, Kisters
K
, Schäfer
U
, Micke
P
, Mücke
R
. Complementary and alternative medicine in lung cancer patients: a neglected phenomenon
. Front Radiat Ther Oncol
. 2010
;42
:198
–205
.9.
Schad
F
, Thronicke
A
, Merkle
A
, Steele
M
, Kröz
M
, Herbstreit
C
, et al. Implementation of an integrative oncological concept in daily care of a German certified Breast Cancer Centre
. Complement Med Res
. 2018
;25
(2
):85
–91
.10.
Melzer
J
, Iten
F
, Hostanska
K
, Saller
R
. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases: a systematic review
. Forsch Komplementmed
. 2009
;16
(4
):217
–26
.11.
Kienle
GS
, Kiene
H
. Review article: influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients – a systematic review of controlled clinical studies
. Integr Cancer Ther
. 2010
;9
(2
):142
–57
.12.
Kovacs
E
, Link
S
, Toffol-Schmidt
U
. Cytostatic and cytocidal effects of mistletoe (Viscum album L.) quercus extract Iscador
. Arzneimittelforschung
. 2006
;56
:467
–73
.13.
Huber
R
, Gründemann
C
. Die Wirkungen der Mistelsubstanz auf das Immunsystem und mögliche Therapeutische Implikationen
. Der Merkurstab
. 2018
;71
(4
):265
–8
.14.
Oei
SL
, Thronicke
A
, Schad
F
. Mistletoe and immunomodulation: insights and implications for anticancer therapies
. Evid Based Complement Alternat Med
. 2019
;2019
:5893017
.15.
Huber
R
, Classen
K
, Werner
M
, Klein
R
. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals
. Arzneimittelforschung
. 2006
;56
(6A
):447
–56
.16.
Klein
R
. Effekte von Mistelextrakten auf immunkompetente Zellen in vitro und in vivo
. In: Scheer
R
, Alban
S
, Becker
H
, Holzgrabe
U
, Kemper
FH
, Kreis
W
, et al., editors. Die Mistel in der Tumortherapie 2
. Essen
: KVC Verlag
; 2009
. p. 185
–193
.17.
Steinborn
C
, Klemd
AM
, Sanchez-Campillo
AS
, Rieger
S
, Scheffen
M
, Sauer
B
, et al. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model
. PLoS One
. 2017
;12
(7
):e0181553
.18.
Braedel-Ruoff
S
. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials
. Forsch Komplementmed
. 2010
;17
(2
):63
–73
.19.
Kienle
GS
, Kiene
H
. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen
. Stuttgart, Germany
: Schattauer Verlag
; 2003
.20.
Urech
K
, Büssing
A
, Thalmann
G
, Schäfermeyer
H
, Heusser
P
. Antiproliferative effects of mistletoe (Viscum album L) extract in urinary bladder carcinoma cell lines
. Anti-Cancer Res
. 2006
;26
:3049
–56
.21.
Kienle
GS
, Kiene
H
. Die Mistel in der Onkologie
. Stuttgart, New York
: Schattauer Verlag
; 2003
. p. 1
–749
.22.
Schad F, Debus M, Soldner G, Thronicke A. Available from: https://www.mistletoe-therapy.org.
23.
Hübner
J
. S3 Leitlinienprojekt: Komplementär- und Alternativmedizin, Komplementärmedizinische Ansätze in der Onkologie, Jahrestagung DGHO 2020 virtuell
. Available from: https://www.virtuell-dgho2020.com/DGHO/dgho-2020.24.
Loef
M
, Walach
H
. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis
. BMC Complement Med Ther
. 2020
;20
(227
):227
.25.
Deng
GE
, Rausch
SM
, Jones
LW
, Gulati
A
, Kumar
NB
, Greenlee
H
, et al. Complementary therapies and integrative medicine in lung cancer: diagnosis and management of lung cancer, 3rd ed –American College of Chest Physicians evidence-based clinical practice guidelines
. Chest
. 2013
;143
(5 Suppl
):e420S
–6
.26.
AWMF-Registernummer
. S3-Leitlinie prävention diagnostik. Therapie und nachsorge des lungenkarzinoms
. Langversion
: AWMF-Registernummer
; 2018
. Available from: https://www.awmf.org/uploads/tx_szleitlinien/020-007OL_l_S3_Lungenkarzinom_2018-03.pdf.27.
Ostermann
T
, Appelbaum
S
, Poier
D
, Boehm
K
, Raak
C
, Büssing
A
. A systematic review and meta-analysis on the survival of cancer patients treated with a fermented Viscum album L. Extract (Iscador): an update of findings
. Complement Med Res
. 2020
;27
:260
–71
.28.
Schad
F
, Thronicke
A
, Steele
M
, Matthes
B
, Grah
C
, Merkle
A
, et al. Overall survival of stage IV non-small cell lung cancer (NSCLC) patients treated with Viscum album L. in additon to standard care
. PloS One
; 2017
. under revision July 2018.29.
Thronicke
A
, Reinhold
T
, von Trott
P
, Matthes
H
, Schad
F
. Cost-effectiveness of real-world administration of concomitant Viscum album L. therapy for the treatment of stage IV pancreatic cancer
. Evid Based Complement Alternat Med
. 2020
;2020
:3543568
.30.
Krebsgesellschaft
D
, Krebshilfe
D
; AWMF
. Konsultationsfassung S3 – Leitlinie Magenkarzinom „Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs”
. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Magenkarzinom/Version_2/LL_Magenkarzinom_Langversion_2.0.pdf.31.
S3-Leitlinie Kolorektales Karzinom. Langversion 2.1. – Januar 2019, AWMF-Registernummer: 021/007OL
. Available from: https://www.awmf.org/uploads/tx_szleitlinien/021-007OLl_S3_Kolorektales-Karzinom-KRK_2019-01.pdf.32.
Zaenker
K
. A specific mistletoe preparation (Iscador-Qu®) in colorectal cancer (CRC) patients: more than just supportive care
. J Cancer Sci Ther
. 2012
;4
:264
–701
.33.
Bock
PR
, Hanisch
J
, Matthes
H
, Zänker
KS
. Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients
. Inflamm Allergy Drug Targets
. 2014
;13
(2
):105
–11
.34.
Friedel
WE
, Matthes
H
, Bock
PR
, Zänker
KS
. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study
. J Soc Integr Oncol
. 2009
;7
(4
):137
–45
.35.
ClinicalTrials.gov. Iscador Qu as Supportive Treatment in Colorectal Cancer (Union International Cancer Control, UICC Stages II-IV), NCT01448655. Available from: https://clinicaltrials.gov/ct2/show/NCT01448655.
36.
Tröger
W
, Galun
D
, Reif
M
, Schumann
A
, Stankovic
N
, Milicévic
M
. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial (Lebensqualität von Patienten mit fortgeschrittenem Pankreaskarzinom unter Misteltherapie)
. Deutsches Ärzteblatt
. 2014
;111
(29–30
):493
–501
.37.
Tröger
W
, Galun
D
, Reif
M
, Schumann
A
, Stankovic
N
, Milicevic
M
. Lebensqualität von Patienten mit fortgeschrittenem Pankreaskarzinom unter Misteltherapie. Eine randomisierte kontrollierte Studie
. Deutsches Ärzteblatt.
. 2014
;111
(29–30
):493
–502
.38.
Tröger
W
, Galun
D
, Reif
M
, Schumann
A
, Stankovic
N
, Milicevic
M
. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival
. Eur J Cancer
. 2013
;49
(18
):3788
–97
.39.
Axtner
J
, Steele
M
, Kröz
M
, Spahn
G
, Matthes
H
, Schad
F
. Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer
. BMC Cancer
. 2016
;16
:579
.40.
Tröger
W
, Galun
D
, Reif
M
, Schumann
A
, Stanković
N
, Milićević
M
. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial
. Dtsch Arztebl Int
. 2014
;111
(29–30
):493
–502
.41.
Matthes
H
, Friedel
WE
, Bock
PR
, Zänker
KS
. Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer
. Curr Mol Med
. 2010
;10
(4
):430
–9
.42.
Greenlee
H
, Balneaves
LG
, Carlson
LE
, Cohen
M
, Deng
G
, Hershman
D
, et al. Clinical practice guidelines on the use of integrative therapies as supportive care in patients treated for breast cancer
. J Natl Cancer Inst Monogr
. 2014
;2014
(50
):346
–58
.43.
Lyman
GH
, Greenlee
H
, Bohlke
K
, Bao
T
, DeMichele
AM
, Deng
GE
, et al. Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline
. J Clin Oncol
. 2018
;36
(25
):2647
–55
.44.
Arbeitsgemeinschaft Gynäkologische Onkologie e.V.
. Kommission Mamma. Leitlinien/Empfehlungen gynäkologische Onkologie Kommission Mamma. Diagnostik und Therapie früher und fortgeschrittener Mammakarzinom. Komplementäre Therapie, Survivorship’
. Available from: https://www.ago-online.de/fileadmin/ago-online/downloads/_leitlinien/kommission_mamma/2020/PDF_DE/2020D%2023_Komplementaermedizin.pdf.45.
Krebsgesellschaft
D
, Krebshilfe
D
; AWMF
. S3: Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms
; 2019
. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.2/LL_Mammakarzinom_Langversion_4.2.pdf.46.
Piao
BK
, Wang
YX
, Xie
GR
, Mannsmann
U
, Matthes
H
, Beuth
J
, et al. Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients: a prospective randomized controlled clinical trial
. Anticancer Res
. 2004
;24
(1
):303
–10
.47.
Tröger
W
, Jezdic
S
, Zdrale
Z
, Tisma
N
, Hamre
HJ
, Matijasevic
M
. Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone
. Breast Cancer
. 2009
;16
(3
):35
–45
.48.
Tröger
W
, Zdrale
Z
, Tisma
N
, Matijasevic
M
. Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: an open randomized clinical pilot trial
. Evidence-Based Complement Alternat Med
. 2014
;2014
.49.
Pelzer
F
, Tröger
W
, Nat
DR
. Complementary treatment with mistletoe extracts during chemotherapy: safety, neutropenia, fever, and quality of life assessed in a randomized study
. J Altern Complement Med
. 2018
;24
(9–10
):954
–61
.50.
Oei
SL
, Thronicke
A
, Kröz
M
, Herbstreit
C
, Schad
F
. Supportive effect of Viscum album L. extracts on the inner feeling of warmth in non-metastasized breast cancer patients
. Eur J Integr Med
. 2017
;27
:97
–104
.51.
Oei
SL
, Thronicke
A
, Kröz
M
, Herbstreit
C
, Schad
F
. The internal coherence of breast cancer patients is associated with the decision-making for chemotherapy and Viscum album L. Treatment
. Evid Based Complement Alternat Med
. 2018
;2018
:1065271
.52.
Oei
SL
, Thronicke
A
, Kröz
M
, Herbstreit
C
, Schad
F
. Supportive effect of Viscum album L. extracts on the sense of coherence in non-metastasized breast cancer patients
. Eur J Integr Med
. 2019
;27
:97
–104
.53.
Oei
SL
, Thronicke
A
, Kröz
M
, Matthes
H
, Schad
F
. Use and safety of Viscum album L applications in cancer patients with preexisting autoimmune diseases: findings from the network oncology study
. Integr Cancer Ther
. 2019
;18
:1534735419832367
.54.
Oei
SL
, Thronicke
A
, Kröz
M
, von Trott
P
, Schad
F
, Matthes
H
. Impact of oncological therapy and Viscum album L treatment on cancer-related fatigue and internal coherence in nonmetastasized breast cancer patients
. Integr Cancer Ther
. 2020
;19
:1534735420917211
.55.
AWMF
. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren
. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Ovarialkarzinom/Version_3__2018_/LL_Ovarialkarzinom_Langversion_3.0.pdf.56.
Grossarth-Maticek
R
, Ziegler
R
. Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador)
. Forsch Komplementmed
. 2007
;14
(3
):140
–7
.57.
Grossarth-Maticek
R
, Ziegler
R
. Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador)
. Eur J Med Res
. 2008
;13
:107
–20
.58.
AWMF.
S3-Leitlinie Diagnostik. Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Version 1.0
; 2018
. https://www.awmf.org/uploads/tx_szleitlinien/032-034OLl_S3_Endometriumkarzinom-Diagnostik-Therpie-Nachsorge_2018-04.pdf.59.
AWMF.
S3-Leitlinie Diagnostik. Therapie und Nachsorge der Patientin mit Zervixkarzinom Version 1.0 – September 2014, AWMF-Registernummer 032/033OL
. https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Zervixkarzinom_2014-10.pdf.60.
Society of Interagative Oncology
. SIO announces collaboration with the American Society of Clinical Oncology (ASCO) to develop two new evidence based guidelines in 2021 and 2022
; 2022
. https://integrativeonc.org/practice-guidelines/announcements/208-announcement-of-sio-asco-collaboration-on-two-more-evidence-based-guidelines-in-2021-22.61.
Thronicke
A
, Schad
, F
, Debus
M
, Grabowski
J
, Soldner
G
. Viscum album L. therapy in oncology: an update on current evidence
. 2021
. Refubium30815 [Preprint]. June 23, 2021. http://dx.doi.org/10.17169/refubium-30815.© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.
